• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.

Anal Cancer | Tumor

Anal Cancer: Locking Out an Intruder

August 24th 2020, 9:00pm

Article

To halt the rise of anal cancer, everyone eligible needs to be vaccinated against HPV, which causes most cases of the disease.

Cancer Related Clinical Care of Sexual and Fender Minorities

February 25th 2020, 12:40am

Article

Sexual and gender minorities are not receiving the same standard of clinical care as other patients with cancer.

Understanding The Relationship Between HPV and Anal Cancer

February 13th 2020, 3:36am

Article

HPV and Anal cancer are associated with one another, here's what you need to know.

Friday Frontline: June 7, 2019

June 7th 2019, 10:00pm

Article

From today’s top entertainers to racial disparities in access to pain treatment, here’s what is making headlines in the cancer space this week.

FDA Approves Age Expansion of HPV Vaccine

October 6th 2018, 1:05am

Article

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.

Driving Research in Rare Cancers

August 7th 2018, 8:13pm

Article

Research continues to drive the oncology field.

Down to the Almighty Dollar: Socioeconomic Status Can Affect Cancer Outcomes

July 25th 2018, 4:58pm

Article

A recent study found that socioeconomic status can play a role in survival for patients with anal cancer.

NCCN Establishes Guidelines for Treating People With HIV and Cancer

February 27th 2018, 7:38pm

Article

Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.

Immunotherapy Treatment Advances in Anal Cancer

August 3rd 2017, 5:34pm

Article

More personalized approaches are being developed to treat patients with metastatic disease.

Despite Benefits, HPV Vaccination Rates Remain Too Low

May 18th 2017, 6:16pm

Article

Despite impressive efficacy for the human papillomavirus (HPV) vaccine reducing the prevalence of high-risk oral HPV infections by 88 percent, many young adults still are not getting the vaccine – sparking concern in the health community.

x